Black Diamond Therapeutics (BDTX) COO, GC awarded 250,000 stock options

Rhea-AI Filing Summary

Black Diamond Therapeutics granted its Chief Operating Officer and General Counsel, Brent Hatzis-Schoch, a stock option for 250,000 shares of common stock on January 21, 2026. The option has an exercise price of $2.57 per share and is scheduled to expire on January 20, 2036.

According to the vesting terms, 25% of the option will vest and become exercisable on January 21, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on his continued service. After this grant, he beneficially owns 250,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hatzis-Schoch Brent

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

245 FIRST STREET, 18TH FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.57	01/21/2026		A		250,000		(1)	01/20/2036	Common Stock	250,000	$0	250,000	D

Explanation of Responses:

1. 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Officer Title: Chief Operating Officer and General Counsel

	/s/ Brent Hatzis-Schoch	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction was reported for BDTX on this Form 4?

The Form 4 reports that Brent Hatzis-Schoch received a stock option for 250,000 shares of Black Diamond Therapeutics common stock.

What is the exercise price of Brent Hatzis-Schoch’s BDTX stock option?

The stock option granted to Brent Hatzis-Schoch has an exercise price of $2.57 per share.

When do the new BDTX stock options start vesting for the COO and General Counsel?

25% of the option will vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued service.

How many BDTX derivative securities does Brent Hatzis-Schoch own after this grant?

Following the reported transaction, Brent Hatzis-Schoch beneficially owns 250,000 derivative securities (stock options) directly.

What is the expiration date of the reported BDTX stock option grant?

The stock option granted to Brent Hatzis-Schoch is scheduled to expire on January 20, 2036.

What is Brent Hatzis-Schoch’s role at Black Diamond Therapeutics (BDTX)?

Brent Hatzis-Schoch serves as Black Diamond Therapeutics’ Chief Operating Officer and General Counsel.